 |
|
Activity of an Interleukin 1 Receptor Antagonist in Rabbit Models of Uveitis
James T. Rosenbaum, MD;
Richard S. Boney
Arch Ophthalmol. 1992;110(4):547-549.
Abstract
| |
• Interleukin 1 has been implicated in intraocular inflammation. The availability of a cloned, recombinant interleukin 1 receptor antagonist has enabled us to test the role of interleukin 1 in specific models of uveitis in New Zealand white rabbits. Seventy-five micrograms of interleukin 1 receptor antagonist injected intravitreally resulted in a 97% reduction in aqueous humor cells present 6 hours after intravitreal injection of 10 ng of human interleukin 1  . Disruption of the blood aqueous barrier was prevented by the receptor antagonist (mean SD aqueous humor protein of 0.6±0.1 g/L in rabbits treated with interleukin 1 receptor antagonist vs 32.2±9.9 g/L in controls). Lower doses of interleukin 1 produced more modest but significant inhibition. Despite the activity of interleukin 1 receptor antagonist in inhibiting interleukin 1-induced inflammation, interleukin 1 receptor antagonist did not produce significant reduction in inflammation subsequent to an active Arthus reaction or subsequent to the intravitreal injection of 125 ng of endotoxin. A potential explanation of these observations is that cytokines in addition to interleukin 1 may be present in sufficient quantities to produce intraocular inflammation or that the effects of interleukin 1 may be primarily intracellular (intracrine) and therefore resistant to the activity of exogenously administered receptor antagonist.
Author Affiliations
From the Oregon Health Sciences University, Portland.
Footnotes
Accepted for publication September 14, 1991.
Reprint requests to the Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201 (Dr Rosenbaum).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Activation of NOD2 in vivo induces IL-1{beta} production in the eye via caspase-1 but results in ocular inflammation independently of IL-1 signaling
Rosenzweig et al.
J. Leukoc. Biol. 2008;84:529-536.
ABSTRACT
| FULL TEXT
Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome
Teoh et al.
Br J Ophthalmol 2007;91:263-264.
FULL TEXT
Suppression of Immune-Mediated Ocular Inflammation in Mice by Interleukin 1 Receptor Antagonist Administration
Lim et al.
Arch Ophthalmol 2005;123:957-963.
ABSTRACT
| FULL TEXT
IL-1 and TNF Receptor-Deficient Mice Show Decreased Inflammation in an Immune Complex Model of Uveitis
Brito et al.
IOVS 1999;40:2583-2589.
ABSTRACT
| FULL TEXT
The Role of Nitric Oxide in Uveitis
Parks et al.
Arch Ophthalmol 1994;112:544-546.
ABSTRACT
|
